Expert Opinion on Drug Discovery

Scope & Guideline

Connecting Experts in Drug Development

Introduction

Welcome to your portal for understanding Expert Opinion on Drug Discovery, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1746-0441
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2006 to 2024
AbbreviationEXPERT OPIN DRUG DIS / Expert. Opin. Drug Discov.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Expert Opinion on Drug Discovery' focuses on providing insights and reviews related to the methodologies and advancements in drug discovery and development. It aims to address various challenges in the field and explore new frontiers that can lead to innovative therapeutic solutions.
  1. Innovative Drug Discovery Strategies:
    The journal emphasizes novel approaches in drug discovery, including the use of artificial intelligence, machine learning, and computational methods to enhance the efficiency and accuracy of drug design.
  2. Targeted Therapeutics Development:
    It covers research aimed at developing drugs targeting specific diseases, particularly in oncology, neurology, and infectious diseases, highlighting the importance of understanding disease mechanisms.
  3. Repurposing Existing Drugs:
    The journal explores strategies for repurposing existing drugs for new therapeutic uses, especially in the context of emerging health crises such as COVID-19.
  4. Translational Research:
    There is a strong focus on bridging the gap between preclinical studies and clinical applications, emphasizing the relevance of animal models and in vitro systems in drug discovery.
  5. Emerging Technologies in Drug Discovery:
    The journal discusses advancements in technologies such as high-throughput screening, nanotechnology, and 3D cell culture models, which are pivotal for modern drug discovery.
  6. Challenges in Drug Development:
    It addresses the various challenges faced in drug development, including issues of bioavailability, drug resistance, and regulatory hurdles.
The journal has seen a significant increase in interest in several emerging themes that reflect the forefront of drug discovery research. These trends indicate a shift towards more integrated and technology-driven approaches.
  1. Artificial Intelligence and Machine Learning:
    There is a growing emphasis on the application of AI and machine learning in drug discovery, focusing on their potential to accelerate the identification and optimization of drug candidates.
  2. Complex Disease Models:
    Research on complex disease models, including polygenic and multifactorial diseases, is trending as scientists seek to better mimic human disease in preclinical settings.
  3. Biologics and RNA-based Therapeutics:
    The exploration of biologics, including monoclonal antibodies and RNA-targeted therapies, has gained traction as a promising area for innovative drug development.
  4. Personalized Medicine Approaches:
    There is an emerging focus on personalized medicine, tailoring drug discovery and development processes to individual patient profiles and genetic backgrounds.
  5. Sustainable and Ethical Drug Discovery:
    Research addressing the ethical implications and sustainability of drug discovery processes, including the use of natural products and environmentally friendly methodologies, is increasingly prominent.

Declining or Waning

While 'Expert Opinion on Drug Discovery' continues to evolve, certain themes have become less prominent in recent publications, reflecting shifts in research focus and emerging methodologies.
  1. Traditional Drug Discovery Techniques:
    There has been a noticeable decline in papers focusing solely on traditional drug discovery methods, as the field increasingly adopts advanced technologies and computational approaches.
  2. General Discussions on Drug Discovery:
    Papers that provide general overviews without a specific focus on innovative methodologies or case studies are becoming less frequent, as the journal seeks to present more targeted and impactful research.
  3. Single Target Drug Discovery:
    The trend towards polypharmacology and multi-target strategies indicates a waning interest in developing drugs that target single pathways or receptors, reflecting a more complex understanding of disease mechanisms.

Similar Journals

ARCHIVES OF PHARMACAL RESEARCH

Exploring the frontiers of pharmacal science for a healthier future.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.

SLAS Discovery

Fostering Collaboration through Open Access Research
Publisher: ELSEVIER SCIENCE INCISSN: 2472-5552Frequency: 10 issues/year

SLAS Discovery is a leading academic journal published by Elsevier Science Inc. that serves as a pivotal resource in the fields of Analytical Chemistry, Biochemistry, Biotechnology, and Molecular Medicine. Since its inception in 2017, the journal has become increasingly influential, attaining a Q1 ranking in Analytical Chemistry and notable Q2 rankings in the associated fields as of 2023. With an impressive Scopus rank that places it within the top percentile of its categories, SLAS Discovery highlights groundbreaking research and methodologies impacting drug discovery and development. The journal advocates for open access, ensuring that its curated content is widely available to the scientific community, fostering collaboration and innovation. Researchers, professionals, and students alike will find value in the journal's comprehensive reviews and original research articles that contribute to the advancement of scientific knowledge and applications in life sciences.

Drug Metabolism and Pharmacokinetics

Connecting Science and Practice in Pharmaceutical Development
Publisher: JAPANESE SOC STUDY XENOBIOTICSISSN: 1347-4367Frequency: 6 issues/year

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.

ACS Pharmacology & Translational Science

Connecting research and practice in pharmacology.
Publisher: AMER CHEMICAL SOCISSN: Frequency: 12 issues/year

ACS Pharmacology & Translational Science is a premier journal published by the American Chemical Society, dedicated to advancing knowledge in the fields of pharmacology and translational science. Operating since 2018, the journal has quickly established itself as a leader in its domain, holding a prestigious Q1 ranking in both Pharmacology and Medical Pharmacology for 2023. With a robust Scopus ranking, it currently occupies the 21st position out of 272 in Medical Pharmacology, reflecting its significant impact within the scientific community at the 92nd percentile. The journal provides an open-access platform for researchers to disseminate innovative findings and viewpoints that bridge the gap between drug discovery and clinical application. In an era where translational research is critical for the success of pharmacological advances, ACS Pharmacology & Translational Science serves as an essential resource for scientists, professionals, and students eager to explore cutting-edge developments in drug development and therapeutic strategies. The journal is based in the United States, with a commitment to fostering collaboration and knowledge sharing across borders.

Current Computer-Aided Drug Design

Transforming Pharmacology with Cutting-Edge Design Techniques
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4099Frequency: 4 issues/year

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

Journal of Pharmaceutical Innovation

Fostering Innovation for Global Health Solutions
Publisher: SPRINGERISSN: 1872-5120Frequency: 4 issues/year

The Journal of Pharmaceutical Innovation, published by SPRINGER, serves as a vital resource in the fields of Pharmaceutical Science and Drug Discovery. With an ISSN of 1872-5120 and an E-ISSN of 1939-8042, this journal has been disseminating significant research findings since its inception in 2006. It is recognized for its rigorous peer-review process, maintaining a respectable ranking of Q2 in Pharmaceutical Science and Q3 in Drug Discovery as of 2023. Researchers and practitioners benefit from the journal's diverse scope, which encompasses innovative methodologies and advancements in pharmaceuticals, thereby fostering knowledge and collaboration within the scientific community. Although it does not offer Open Access options, the journal is accessible through institutional subscriptions and libraries, ensuring that critical insights in drug development and pharmacology reach a broad audience. The geographical presence of the journal in the United States underscores its influence in shaping the pharmaceutical landscape on a global scale.

MEDICINAL RESEARCH REVIEWS

Unveiling Insights for Tomorrow’s Health Solutions
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Drug Research

Illuminating Pathways in Pharmacological Studies
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

International Journal for Parasitology-Drugs and Drug Resistance

Advancing Knowledge in Parasitology and Drug Resistance
Publisher: ELSEVIER SCI LTDISSN: 2211-3207Frequency: 3 issues/year

International Journal for Parasitology-Drugs and Drug Resistance, published by ELSEVIER SCI LTD, is a premier open access journal that has been at the forefront of parasitology research since its inception in 2011. With an impressive impact factor and recognition as a Q1 journal in multiple categories including Infectious Diseases, Parasitology, and Pharmacology, it serves as an essential resource for researchers, professionals, and students looking to advance their understanding of drug resistance and therapeutic strategies against parasitic infections. Based in the Netherlands, the journal’s scope encompasses a wide range of topics dedicated to innovative drug development, resistance mechanisms, and treatment efficacy, empowering the scientific community with high-quality, peer-reviewed articles. Engaging with this publication not only enhances the discourse on parasitological challenges but also contributes to the global fight against infectious diseases. With the adoption of open access since 2011, the journal ensures that valuable insights and knowledge remain readily accessible to all stakeholders in the field.

Pharmaceutical Sciences

Bridging research and practice to transform healthcare.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.